Sol Gel Technologies (SLGL) Rating Grow to Purchase at Zacks Investment Research

Sol Gel Technologies (SLGL) Rating Grow to Purchase at Zacks Investment Research

Sol Gel Technologies (NASDAQ:SLGL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The firm presently has a $7.25 price target on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 11.54% from the stock’s previous close.

According to Zacks, “Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. “

A number of other equities research analysts have also issued reports on SLGL. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of Sol Gel Technologies in a research note on Wednesday, December 5th. ValuEngine downgraded Sol Gel Technologies from a “buy” rating to a “hold” rating in a report on Friday, December 21st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Sol Gel Technologies has a consensus rating of “Buy” and a consensus target price of $16.65.

SLGL stock remained flat at $$6.50 on Tuesday. The company had a trading volume of 500 shares, compared to its average volume of 10,750. Sol Gel Technologies has a 12-month low of $5.41 and a 12-month high of $12.77. The stock has a market cap of $122.60 million and a price-to-earnings ratio of -1.29.

Sol Gel Technologies (NASDAQ:SLGL) last posted its earnings results on Tuesday, November 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.16. The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.05 million. On average, equities research analysts anticipate that Sol Gel Technologies will post -1.8 EPS for the current fiscal year.

An institutional investor recently bought a new position in Sol Gel Technologies stock. Raymond James & Associates acquired a new position in Sol Gel Technologies Ltd (NASDAQ:SLGL) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 13,260 shares of the company’s stock, valued at approximately $102,000. Raymond James & Associates owned 0.07% of Sol Gel Technologies as of its most recent filing with the SEC. Institutional investors and hedge funds own 20.32% of the company’s stock.

Sol Gel Technologies Company Profile

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.

See Also: Consumer Price Index (CPI)

Get a free copy of the Zacks research report on Sol Gel Technologies (SLGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment